Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.
Nexcella has raised $8.0M in total funding. The most recent round was Grant. The last funding was announced in July 2024.
Nexcella's investors include California Institute for Regenerative Medicine.
Nexcella is headquartered in Los Angeles, United States.
Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.
Nexcella is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nexcella — Funding & Investors." VCBacked, July 25, 2024, https://www.vcbacked.co/company/nexcella. Accessed August 14, 2026.
VCBacked. (2024). Nexcella — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nexcella
{{cite web |title=Nexcella — Funding & Investors |url=https://www.vcbacked.co/company/nexcella |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated